Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1Classical hematology 1

Conditions

Lymphoma, Mantle-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Epoetin Alfa 38Darbepoetin alfa 30epoetin beta 10Rivaroxaban 9olaparib 5eltrombopag 5apixaban 5Heparin, Low-Molecular-Weight 5pegylated granulocyte colony-stimulating factor 4pegfilgrastim 4emicizumab 4Gemcitabine 4Filgrastim 4Dalteparin 4Cyclophosphamide 4AP 1903 reagent 4romiplostim 3peginesatide 3luspatercept 3hetrombopag 3hematide 3Vancomycin 3ON 01910 3Enoxaparin 3Azacitidine 3ACE-011 3venetoclax 2telapristone acetate 2roxadustat 2iron isomaltoside 1000 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Calcineurin Inhibitors × Classical hematology × Clear all
NCT03320642 2025-10-21

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Incyte Corporation

Phase 1 Terminated
84 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Hodgkin Disease, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Hematologic Neoplasms, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡